New Long-Acting HIV shot tested in healthy people

NCT ID NCT05112939

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a long-acting injectable form of the HIV drug rilpivirine, alone or with another drug called cabotegravir, in 126 healthy adults. The goal was to see how the body processes the drugs and whether they are safe. This trial does not test treatment or prevention of HIV, but gathers important safety and dosing information for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

rilpivirine and cabotegravir long-acting injections

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • PRA Health Sciences

    Groningen, NZ 9728, Netherlands

  • PRA Health Sciences 1

    Salt Lake City, Utah, 84124, United States

  • PRA Health Sciences 2

    Lenexa, Kansas, 66219, United States